title: Conjugated linoleic acids alter bone fatty acid composition and reduce ex vivo prostaglandin E2 biosynthesis in rats fed n-6 or n-3 fatty acids.
abstract: This study evaluated the effects of conjugated linoleic acids (CLA) on tissue fatty acid composition and ex vivo prostaglandin E2 (PGE2) production in rats given diets varying in n-6 and n-3 fatty acids. Four groups of rats were given a basal semipurified diet (AIN-93G) containing 70 g/kg of added fat for 42 d. The fat treatments were formulated to contain CLA (0 vs. 10 g/kg of diet) and n-6 (soybean oil having an n-6/n-3 ratio of 7.3) and n-3 fatty acids (menhaden oil + safflower oil having an n-6/n-3 ratio of 1.8) in different ratios in a 2 x 2 factorial design. Fatty acids in liver, serum, muscle, heart, brain, spleen, and bone (cortical, marrow, and periosteum) were analyzed by capillary gas-liquid chromatography. The various dietary lipid treatments did not affect growth; however, CLA improved feed efficiency. The CLA isomers were found in all rat tissues analyzed although their concentrations varied. Dietary CLA decreased the concentrations of 16:1n-7, 18:1, total monounsaturates and n-6 fatty acids, but increased the concentrations of n-3 fatty acids (22:5n-3 and 22:6n-3), and saturates in the tissues analyzed. Ex vivo PGE2 production in bone organ culture was decreased by n-3 fatty acids and CLA. We speculate that CLA reduced the concentration of 18:1 fatty acids by inhibiting liver delta9-desaturase activity. The fact that CLA lowered ex vivo PGE2 production in bone organ culture suggests that these conjugated fatty acids have the potential to influence bone formation and resorption.
authors.affiliation: Department of Food Science, Purdue University, West Lafayette, Indiana 47907, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: B A
authors.initials: BA
authors.lastname: Watkins
mesh_terms: D000821:Animal Feed; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D001853:Bone Marrow / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D001842:Bone and Bones / Q000737:chemistry / Q000187:drug effects*; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D001923:Brain Chemistry / Q000187:drug effects; D015232:Dinoprostone / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D004435:Eating; D005227:Fatty Acids / Q000032:analysis / Q000737:chemistry*; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry / Q000378:metabolism; D008041:Linoleic Acids / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D008099:Liver / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051381:Rats; D013154:Spleen / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors; D014018:Tissue Distribution
chemical_list: D005227:Fatty Acids; D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated; D008041:Linoleic Acids; D015232:Dinoprostone